Navigation Links
Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
Date:5/30/2012

THE WOODLANDS, Texas, May 30, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer, will present at the Jefferies 2012 Global Healthcare Conference on Wednesday, June 6 at 11:00 a.m. Eastern Time in New York City. Dr. Zambrowicz will provide an overview of Lexicon's clinical development programs and milestones.

A live webcast of the presentation will be available through Lexicon's corporate website at www.lexpharma.com. An archived version of the presentation will be available for 30 days after the event.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome, rheumatoid arthritis and glaucoma, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon to Provide First Quarter 2012 Financial Results
4. Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
5. Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference
6. Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012
7. Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Lexicon Announces Commencement of Rights Offering to Stockholders
9. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
10. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
11. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 Germany Cataract Surgery ... new report, "Germany Cataract Surgery Devices Market Outlook to ... Surgery Devices market. The report provides value, in millions ... (USD) within market segements - Phacoemulsification Equipment and Ophthalmic ... shares and distribution shares data for each of these ...
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda ... will release results for the fourth quarter of 2016 on Wednesday, ... ... at 4:30 PM ET on Wednesday, February 15, 2017, during which ... results and other corporate activities. To participate in the conference call, ...
(Date:1/19/2017)... 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, ... The global anti-obesity drugs market is expected to grow ... forecast period and CAGR of 38.7% in the second half of ... CAGR of 32.8% from 2016 to 2027. The market is estimated ... million in 2027. ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation ... author, Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native ... Mark Hardy , “While sitting up in bed, I felt a pounding headache. It ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
(Date:1/19/2017)... ... , ... This month, the CEO and Clinical Director of Sober Living Outpatient, ... in Delray Beach, Florida has been changed from Sober Living Outpatient to ‘SLO Recovery ... Hoffman and Chris Farley are dying from heroin overdoses, but thousands of unnamed kids ...
(Date:1/19/2017)... ... 19, 2017 , ... Remote Medical Technologies (RMT), the leader ... with their iMedHD2™ Portable Teleultrasound System. Compatible with any ultrasound ... HD, dynamic, streaming ultrasound images and video to one or more distant locations ...
(Date:1/19/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it will be co-hosting a workshop entitled “Develop Better ... delivery solutions to health industries worldwide. The one day event is to be ...
Breaking Medicine News(10 mins):